Transcept Pharmaceuticals
As of the edition of 20 October 2026, Transcept Pharmaceuticals runs 4 drugs, 4 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fluticasone propionate | none listed | 2 |
| Zolpidem | none listed | 0 |
| Fluticasone | none listed | 2 |
| Omadacycline | Ends 2030 (patent) | 0 |
A route B row is one company at one target.
Where its trials are
- Infections: 10 trials led
- Lungs and airways: 3 trials led
- Skin and connective tissue: 3 trials led